330 related articles for article (PubMed ID: 22961335)
61. Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection.
Yu H; Tudor D; Alfsen A; Labrosse B; Clavel F; Bomsel M
Retrovirology; 2008 Oct; 5():93. PubMed ID: 18925934
[TBL] [Abstract][Full Text] [Related]
62. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
63. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
Korazim O; Sackett K; Shai Y
J Mol Biol; 2006 Dec; 364(5):1103-17. PubMed ID: 17045292
[TBL] [Abstract][Full Text] [Related]
64. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
[TBL] [Abstract][Full Text] [Related]
65. Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion.
He Y
Curr Pharm Des; 2013; 19(10):1800-9. PubMed ID: 23092277
[TBL] [Abstract][Full Text] [Related]
66. The C34 Peptide Fusion Inhibitor Binds to the Six-Helix Bundle Core Domain of HIV-1 gp41 by Displacement of the C-Terminal Helical Repeat Region.
Louis JM; Baber JL; Clore GM
Biochemistry; 2015 Nov; 54(45):6796-805. PubMed ID: 26506247
[TBL] [Abstract][Full Text] [Related]
67. An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.
Liu Y; Ke Z; Wu KY; Liu S; Chen WH; Jiang S; Jiang ZH
ChemMedChem; 2011 Sep; 6(9):1654-64. PubMed ID: 21688394
[TBL] [Abstract][Full Text] [Related]
68. Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.
Wu X; Liu Z; Ding X; Yu D; Wei H; Qin B; Zhu Y; Chong H; Cui S; He Y
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321334
[TBL] [Abstract][Full Text] [Related]
69. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.
He Y; Cheng J; Lu H; Li J; Hu J; Qi Z; Liu Z; Jiang S; Dai Q
Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16332-7. PubMed ID: 18852475
[TBL] [Abstract][Full Text] [Related]
70. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.
Lai W; Wang C; Yan J; Liu H; Zhang W; Lin B; Xi Z
Bioorg Med Chem; 2020 Feb; 28(4):115214. PubMed ID: 31932193
[TBL] [Abstract][Full Text] [Related]
71. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
Melikyan GB; Egelhofer M; von Laer D
J Virol; 2006 Apr; 80(7):3249-58. PubMed ID: 16537592
[TBL] [Abstract][Full Text] [Related]
72. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
An T; Ouyang W; Pan W; Guo D; Li J; Li L; Chen G; Yang J; Wu S; Tien P
Antiviral Res; 2012 Jun; 94(3):276-87. PubMed ID: 22426469
[TBL] [Abstract][Full Text] [Related]
73. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
Nameki D; Kodama E; Ikeuchi M; Mabuchi N; Otaka A; Tamamura H; Ohno M; Fujii N; Matsuoka M
J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
[TBL] [Abstract][Full Text] [Related]
74. Increase of anti-HIV activity of C-peptide fusion inhibitors using a bivalent drug design approach.
Ling Y; Xue H; Jiang X; Cai L; Liu K
Bioorg Med Chem Lett; 2013 Sep; 23(17):4770-3. PubMed ID: 23906421
[TBL] [Abstract][Full Text] [Related]
75. An effective conjugation strategy for designing short peptide-based HIV-1 fusion inhibitors.
Liang G; Wang H; Chong H; Cheng S; Jiang X; He Y; Wang C; Liu K
Org Biomol Chem; 2016 Aug; 14(33):7875-82. PubMed ID: 27454320
[TBL] [Abstract][Full Text] [Related]
76. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins.
Steffen I; Pöhlmann S
Curr Pharm Des; 2010; 16(9):1143-58. PubMed ID: 20030613
[TBL] [Abstract][Full Text] [Related]
77. Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.
Izumi K; Kodama E; Shimura K; Sakagami Y; Watanabe K; Ito S; Watabe T; Terakawa Y; Nishikawa H; Sarafianos SG; Kitaura K; Oishi S; Fujii N; Matsuoka M
J Biol Chem; 2009 Feb; 284(8):4914-20. PubMed ID: 19073606
[TBL] [Abstract][Full Text] [Related]
78. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
Li W; Lu L; Li W; Jiang S
Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
[TBL] [Abstract][Full Text] [Related]
79. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.
Dwyer JJ; Hasan A; Wilson KL; White JM; Matthews TJ; Delmedico MK
Biochemistry; 2003 May; 42(17):4945-53. PubMed ID: 12718536
[TBL] [Abstract][Full Text] [Related]
80. Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action.
Wang C; Cheng S; Zhang Y; Ding Y; Chong H; Xing H; Jiang S; Li X; Ma L
Viruses; 2019 Sep; 11(9):. PubMed ID: 31480738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
